---
title: "PRAXIS 警报：Bragar Eagel & Squire, P.C. 正在代表 Praxis Precision Medicines 的股东进行调查，并鼓励投资者与该律所联系"
description: "Bragar Eagel & Squire, P.C. 正在代表可能遭受损失的股东调查 Praxis Precision Medicines, Inc.。该调查重点关注在 Praxis 发布 2025 年第二季度财务结果后，可能违反联邦证券法的情况。财务结果显示其抗癫痫药物研究中出现不良事件，导致股价下跌 5.55%。鼓励投资者联系该公司以了解法律选择"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/254281372.md"
published_at: "2025-08-23T14:33:23.000Z"
---

# PRAXIS 警报：Bragar Eagel & Squire, P.C. 正在代表 Praxis Precision Medicines 的股东进行调查，并鼓励投资者与该律所联系

> Bragar Eagel & Squire, P.C. 正在代表可能遭受损失的股东调查 Praxis Precision Medicines, Inc.。该调查重点关注在 Praxis 发布 2025 年第二季度财务结果后，可能违反联邦证券法的情况。财务结果显示其抗癫痫药物研究中出现不良事件，导致股价下跌 5.55%。鼓励投资者联系该公司以了解法律选择

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis ( PRAX ) To Contact Him Directly To Discuss Their Options

### Related Stocks

- [PRAX.US - Praxis Precision Medicines](https://longbridge.com/zh-CN/quote/PRAX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Praxis Precision Medicines edges down after $575 mln stock sale | Praxis Precision Medicines shares fell 0.5% to $271.50 following a $575 million stock sale, where approximately 2.2 mill | [Link](https://longbridge.com/zh-CN/news/271799539.md) |
| Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages | Praxis Precision Medicines, Inc. (NASDAQ:PRAX) has received a consensus rating of "Moderate Buy" from eighteen research  | [Link](https://longbridge.com/zh-CN/news/272508104.md) |
| Praxis Precision Medicines Highlights CNS Drug Pipeline and Commercial Strategy in New Presentation | Praxis Precision Medicines Inc. updated its late-stage CNS drug pipeline, highlighting therapies like ulixacaltamide for | [Link](https://longbridge.com/zh-CN/news/272275638.md) |
| Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering \| PRAX Stock News | Praxis Precision Medicines, Inc. has announced the pricing of its public offering of 2,212,000 shares at $260.00 per sha | [Link](https://longbridge.com/zh-CN/news/271735280.md) |
| BUZZ-Praxis Precision Medicines slips after announcing equity offering plans | Praxis Precision Medicinesshares fell 4% to $262.01 after announcing plans for an equity offering. The deal size is undi | [Link](https://longbridge.com/zh-CN/news/271701379.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。